Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 73 articles:
HTML format
Text format



Single Articles


    April 2017
  1. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
    Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
    PubMed     Text format     Abstract available


    March 2017
  2. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
    Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
    Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
    PubMed     Text format     Abstract available


    February 2017
  3. RATHKOPF DE, Antonarakis ES, Shore ND, Tutrone RF, et al
    Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
    Clin Cancer Res. 2017 Feb 17. pii: clincanres.2509.2016.
    PubMed     Text format     Abstract available


  4. SAXENA R, Yang C, Rao M, Turaga RC, et al
    Preclinical development of a non-toxic oral formulation of monoethanolamine, a lipid precursor, for prostate cancer treatment.
    Clin Cancer Res. 2017 Feb 6. pii: clincanres.1716.2016.
    PubMed     Text format     Abstract available


    January 2017
  5. WANG R, Wang J, Gao G, Hu J, et al
    Pre-biopsy mp-MRI can help to improve the predictive performance in prostate cancer: a prospective study in 1478 consecutive patients.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2884.2016.
    PubMed     Text format     Abstract available


  6. KIM K, Zhang H, LaRosa S, Jebiwott S, et al
    Bombesin Antagonist Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
    Clin Cancer Res. 2017 Jan 20. pii: clincanres.2745.2016.
    PubMed     Text format     Abstract available


  7. CASTIELLO L, Sabatino M, Ren J, Terabe M, et al
    Expression of CD14, IL-10 and tolerogenic signature in dendritic cells inversely correlate with response to TARP vaccination in prostate cancer patients.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2199.2016.
    PubMed     Text format     Abstract available



  8. Correction: Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:323.
    PubMed     Text format    


    December 2016
  9. LAM HM, McMullin R, Nguyen H, Coleman I, et al
    Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2054.2016.
    PubMed     Text format     Abstract available


    November 2016
  10. ANTONARAKIS ES, Kibel AS, Yu EY, Karsh LI, et al
    Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically-Recurrent Prostate Cancer: A Phase II Randomized Trial.
    Clin Cancer Res. 2016 Nov 10. pii: clincanres.1780.2016.
    PubMed     Text format     Abstract available


  11. YIN Y, Zhang Q, Zhang H, He Y, et al
    Molecular signature to risk-stratify prostate cancer of intermediate risk.
    Clin Cancer Res. 2016 Nov 1. pii: clincanres.2400.2016.
    PubMed     Text format     Abstract available


    October 2016
  12. PENET MF, Kakkad S, Pathak AP, Krishnamachary B, et al
    Structure and Function of a Prostate Cancer Dissemination Permissive Extracellular Matrix.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1516.2016.
    PubMed     Text format     Abstract available


  13. SAYYID R, Evans A, Hersey K, Maloni R, et al
    A Phase II, Randomized, Open Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Clin Cancer Res. 2016 Oct 18. pii: clincanres.1790.2016.
    PubMed     Text format     Abstract available


  14. PALAPATTU GS, Salami SS, Cani AK, Hovelson DH, et al
    Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.
    Clin Cancer Res. 2016 Oct 7. doi: 10.1158/1078-0432.CCR-16-1454.
    PubMed     Text format     Abstract available


  15. KUHN P, Carlsson A, Luttgen MS, Dizon KK, et al
    Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1355.2016.
    PubMed     Text format     Abstract available


    September 2016
  16. TAPLIN ME, McKay RR, Werner L, Mostaghel EA, et al
    A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 28. pii: clincanres.0987.2016.
    PubMed     Text format     Abstract available


  17. BRAGELMANN J, Klumper N, Offermann A, von Massenhausen A, et al
    Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.0094.2016.
    PubMed     Text format     Abstract available


  18. HELLER G, Fizazi K, McCormack RT, Molina A, et al
    The added value of circulating tumour cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1224.2016.
    PubMed     Text format     Abstract available


  19. LUK IS, Shrestha R, Xue H, Wang Y, et al
    BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0718.2016.
    PubMed     Text format     Abstract available


  20. GUPTA S, Li J, Kemeny G, Bitting RL, et al
    Whole genomic copy number alterations in circulating tumor cells from men with abiraterone or enzalutamide resistant metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1211.2016.
    PubMed     Text format     Abstract available


    August 2016
  21. QU F, Xie W, Nakabayashi M, Zhang H, et al
    Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.1070.2016.
    PubMed     Text format     Abstract available


  22. REBELLO RJ, Kusnadi E, Cameron DP, Pearson HB, et al
    The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer.
    Clin Cancer Res. 2016 Aug 2. pii: clincanres.0124.2016.
    PubMed     Text format     Abstract available


    July 2016
  23. SHOURIDEH M, Azabdaftari G, Attwood K, DePriest A, et al
    GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016.
    PubMed     Text format     Abstract available


  24. SAYLOR PJ, Lee RJ, Arora KS, Deshpande V, et al
    Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0237.2016.
    PubMed     Text format     Abstract available



  25. Correction: Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
    Clin Cancer Res. 2016;22:3702.
    PubMed     Text format    


    June 2016
  26. ZHAO S, Geybels MS, Leonardson A, Rubicz R, et al
    Epigenome-wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-lethal Progression in Men with Clinically Localized Prostate Cancer.
    Clin Cancer Res. 2016 Jun 29. pii: clincanres.0549.2016.
    PubMed     Text format     Abstract available


  27. SHARP A, Welti J, Blagg J, de Bono JS, et al
    Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Jun 21. pii: clincanres.1137.2016.
    PubMed     Text format     Abstract available


  28. BANSAL N, Bartucci M, Yusuff S, Davis S, et al
    BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.3107.2015.
    PubMed     Text format     Abstract available


  29. YAMIN G, Schenker-Ahmed NM, Shabaik A, Adams D, et al
    Voxel Level Radiologic-Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer.
    Clin Cancer Res. 2016;22:2668-74.
    PubMed     Text format     Abstract available


    May 2016
  30. GUEDES L, Morais C, Almutairi F, Haffner MC, et al
    Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.
    Clin Cancer Res. 2016 May 10. pii: clincanres.0205.2016.
    PubMed     Text format     Abstract available


  31. YANG YC, Banuelos CA, Mawji NR, Wang J, et al
    Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer.
    Clin Cancer Res. 2016 May 2. pii: clincanres.2901.2015.
    PubMed     Text format     Abstract available


    April 2016
  32. CHEN X, Li Q, Liu X, Liu C, et al
    Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer (CRPC).
    Clin Cancer Res. 2016 Apr 8. pii: clincanres.2956.2015.
    PubMed     Text format     Abstract available


    March 2016
  33. LOPEZ SM, Agoulnik AI, Zhang M, Peterson LE, et al
    Nuclear Receptor Corepressor 1 expression and output declines with prostate cancer progression.
    Clin Cancer Res. 2016 Mar 11. pii: clincanres.1983.2015.
    PubMed     Text format     Abstract available


  34. GAO S, Ye H, Gerrin S, Wang H, et al
    ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.2309.2015.
    PubMed     Text format     Abstract available


    February 2016
  35. MORRIS MJ, Rathkopf DE, Novotny W, Gibbons JA, et al
    Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Feb 8. pii: clincanres.2638.2015.
    PubMed     Text format     Abstract available


  36. HUSSAIN M, Le Moulec S, Gimmi C, Bruns R, et al
    Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-resistant Prostate Cancer.
    Clin Cancer Res. 2016 Feb 2. pii: clincanres.2512.2015.
    PubMed     Text format     Abstract available


  37. HEDAYATI M, Haffner MC, Coulter J, Raval RR, et al
    Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation.
    Clin Cancer Res. 2016 Feb 1. pii: clincanres.1147.2015.
    PubMed     Text format     Abstract available


    January 2016
  38. LENNARTZ M, Minner S, Brasch S, Wittmann H, et al
    The combination of DNA ploidy status and PTEN/6q15 deletions provides strong and independent prognostic information in prostate cancer.
    Clin Cancer Res. 2016 Jan 26. pii: clincanres.0635.2015.
    PubMed     Text format     Abstract available


  39. CHOI SY, Xue H, Wu R, Fazli L, et al
    The MCT4 Gene: a Novel, Potential Target for Therapy of Advanced Prostate Cancer.
    Clin Cancer Res. 2016 Jan 11. pii: clincanres.1624.2015.
    PubMed     Text format     Abstract available



  40. Retraction: Suppression of N-Methyl-N-nitrosourea/Testosterone-Induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s).
    Clin Cancer Res. 2016;22:270.
    PubMed     Text format    


  41. HABERKORN U, Eder M, Kopka K, Babich JW, et al
    New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
    Clin Cancer Res. 2016;22:9-15.
    PubMed     Text format     Abstract available


    December 2015
  42. ZHANG W, Yi B, Wang C, Chen D, et al
    Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.1927.2015.
    PubMed     Text format     Abstract available


  43. VAN LEEUWEN FW, van der Poel HG
    Surgical Guidance in Prostate Cancer: "From Molecule to Man" Translations.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2575.2015.
    PubMed     Text format     Abstract available


  44. KATO M, Banuelos CA, Imamura Y, Leung JK, et al
    Co-targeting Androgen Receptor Splice Variants and mTOR signaling pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2119.2015.
    PubMed     Text format     Abstract available


  45. BELTRAN H, Jendrisak A, Landers M, Mosquera JM, et al
    The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
    Clin Cancer Res. 2015 Dec 15. pii: clincanres.0137.2015.
    PubMed     Text format     Abstract available


  46. ZHAO SG, Evans JR, Kothari V, Sun G, et al
    The landscape of prognostic outlier genes in high-risk prostate cancer.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.1250.2015.
    PubMed     Text format     Abstract available


    November 2015
  47. GEVENSLEBEN H, Dietrich D, Golletz C, Steiner S, et al
    The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer.
    Clin Cancer Res. 2015 Nov 16. pii: clincanres.2042.2015.
    PubMed     Text format     Abstract available


  48. MEHRA N, Zafeiriou Z, Lorente D, Terstappen LW, et al
    CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.
    Clin Cancer Res. 2015;21:4992-5.
    PubMed     Text format     Abstract available


  49. YANG Y, Jia D, Kim H, Abd Elmageed ZY, et al
    Dysregulation of microRNA-212 Promotes Castration Resistance via hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.
    Clin Cancer Res. 2015 Nov 9. pii: clincanres.1606.2015.
    PubMed     Text format     Abstract available


  50. MONTGOMERY B, Eisenberger MA, Rettig MB, Chu FM, et al
    Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2015 Nov 2. pii: clincanres.1432.2015.
    PubMed     Text format     Abstract available


  51. WANG T, Song W, Chen Y, Chen R, et al
    Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.
    Clin Cancer Res. 2015 Nov 2. pii: clincanres.1632.2015.
    PubMed     Text format     Abstract available


    October 2015
  52. LU D, Sinnott JA, Valdimarsdottir UA, Fang F, et al
    Stress-Related Signaling Pathways in Lethal and Non-Lethal Prostate Cancer.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.0101.2015.
    PubMed     Text format     Abstract available


  53. SONN GA, Behesnilian AS, Jiang ZK, Zettlitz KA, et al
    Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real-Time.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.0503.2015.
    PubMed     Text format     Abstract available


  54. YUN EJ, Zhou J, Lin CJ, Hernandez E, et al
    Targeting cancer stem cell in castration resistant prostate cancer.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.0190.2015.
    PubMed     Text format     Abstract available


  55. ZELIC R, Fiano V, Zugna D, Grasso C, et al
    Gene-specific hypermethylation (GSTP1) and global hypomethylation (LINE-1) on initial negative prostate biopsy as markers of prostate cancer on a rebiopsy.
    Clin Cancer Res. 2015 Oct 16. pii: clincanres.0606.2015.
    PubMed     Text format     Abstract available


  56. HURLEY PJ, Sundi D, Shinder B, Simons B, et al
    Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer.
    Clin Cancer Res. 2015 Oct 7. pii: clincanres.0256.2015.
    PubMed     Text format     Abstract available



  57. Correction: The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients.
    Clin Cancer Res. 2015;21:4496.
    PubMed     Text format    


    August 2015
  58. ARMSTRONG AJ, Zhang T
    Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
    Clin Cancer Res. 2015 Aug 25. pii: clincanres.1613.2015.
    PubMed     Text format     Abstract available


  59. AUVINEN A, Moss S, Tammela TL, Taari K, et al
    Absolute Effect of Prostate Cancer Screening: Balance of benefits and harms by center within the European Randomized Study of Prostate Cancer Screening.
    Clin Cancer Res. 2015 Aug 19. pii: clincanres.0941.2015.
    PubMed     Text format     Abstract available


  60. WANG X, Huang Y, Christie AL, Bowden M, et al
    Cabozantinib inhibits abiraterone's upregulation of IGF-1R phosphorylation and enhances its anti-prostate cancer activity.
    Clin Cancer Res. 2015 Aug 19. pii: clincanres.0824.2015.
    PubMed     Text format     Abstract available


  61. VARKARIS A, Corn PG, Parikh NU, Efstathiou E, et al
    Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer.
    Clin Cancer Res. 2015 Aug 13. pii: clincanres.0235.2015.
    PubMed     Text format     Abstract available


  62. LECLERC BG, Charlebois R, Chouinard G, Allard B, et al
    CD73 expression is an independent prognostic factor in prostate cancer.
    Clin Cancer Res. 2015 Aug 7. pii: clincanres.1181.2015.
    PubMed     Text format     Abstract available


    July 2015
  63. CUI D, Dai J, Keller JM, Mizokami A, et al
    Notch pathway inhibition using PF-03084014, a gamma-secretase inhibitor (GSI), enhances the anti-tumor effect of docetaxel in prostate cancer.
    Clin Cancer Res. 2015 Jul 22. pii: clincanres.0242.2015.
    PubMed     Text format     Abstract available


  64. PANDIT-TASKAR N, O'Donoghue JA, Durack JC, Lyashchenko SK, et al
    A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
    Clin Cancer Res. 2015 Jul 14. pii: clincanres.0552.2015.
    PubMed     Text format     Abstract available


    June 2015
  65. YAMAMOTO Y, Lin PJ, Beraldi E, Zhang F, et al
    siRNA lipid nanoparticle potently silence clusterin and delay progression when combined with androgen receptor co-targeting in enzalutamide resistant prostate cancer.
    Clin Cancer Res. 2015 Jun 23. pii: clincanres.0866.2015.
    PubMed     Text format     Abstract available


  66. WANG BD, Ceniccola K, Yang Q, Andrawis R, et al
    Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities.
    Clin Cancer Res. 2015 Jun 18. pii: clincanres.1566.2014.
    PubMed     Text format     Abstract available


  67. CAI C, Chen QB, Han ZD, Zhang YQ, et al
    miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer.
    Clin Cancer Res. 2015 Jun 16. pii: clincanres.0217.2015.
    PubMed     Text format     Abstract available


  68. WANG N, Yao M, Xu J, Quan Y, et al
    Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK-mediated phosphorylation of Akt.
    Clin Cancer Res. 2015 Jun 12. pii: clincanres.3163.2014.
    PubMed     Text format     Abstract available


  69. ZHANG X, Coleman I, Brown LG, True LD, et al
    SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2015 Jun 12. pii: clincanres.0157.2015.
    PubMed     Text format     Abstract available


    May 2015
  70. ZHU Y, Liu C, Armstrong C, Lou W, et al
    Anti-androgens inhibit ABCB1 efflux and ATPase activity and reverse docetaxel resistance in advanced prostate cancer.
    Clin Cancer Res. 2015 May 20. pii: clincanres.0269.2015.
    PubMed     Text format     Abstract available


  71. HOSSAIN DM, Pal SK, Moreira DF Dfm, Duttagupta P, et al
    TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Clin Cancer Res. 2015 May 12. pii: clincanres.3145.2014.
    PubMed     Text format     Abstract available


    March 2015
  72. SHARIFI N
    Steroid sidestep: evading androgen ablation by abiraterone.
    Clin Cancer Res. 2015;21:1240-2.
    PubMed     Text format     Abstract available


    January 2015
  73. CHANG E, Liu H, Unterschemmann K, Ellinghaus P, et al
    18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.
    Clin Cancer Res. 2015;21:335-46.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: